Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | FGR | P09769 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31123875 | 0.81 | DGAT1 (0.34) | RET | |
| SCHEMBL21801411 | 0.81 | RET (0.46) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178853 | 0.76 | RET (0.76) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL31639888 | 0.76 | RET (0.76) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178845 | 0.76 | RET (0.75) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL31070110 | 0.75 | DGAT1 (0.33) | — | |
| SCHEMBL21678372 | 0.75 | DGAT1 (0.33) | — | |
| SCHEMBL16259168 | 0.75 | ADK (0.40) | — | |
| SCHEMBL31340598 | 0.75 | ADK (0.40) | — | |
| SCHEMBL22502469 | 0.75 | SRC (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3849986-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | RET 1/4885CYP1A2 3948/4885HCK 259/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | RET 1/4885CYP1A2 3948/4885HCK 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.